FORM	4
------	---

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT (	OF CHANGES	IN BENEFICIAL	<b>OWNERSHIP</b>
-------------	------------	---------------	------------------

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

			or Section 30(ii) of the investment Company Act of 1940			
1. Name and Address of Reporting Person* <u>Hofmeister Robert</u>		n*	2. Issuer Name <b>and</b> Ticker or Trading Symbol TCR2 THERAPEUTICS INC. [ TCRR ] -		tionship of Reporting Pers all applicable) Director Officer (give title	10% Owner Other (specify
_	t) (First) (Middle) R2 THERAPEUTICS INC. DEINNEY STREET		3. Date of Earliest Transaction (Month/Day/Year) 04/11/2019	X	below) Chief Scientific C	below) Officer
(Street) CAMBRIDGE (City)	MA (State)	02142 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line) X	idual or Joint/Group Filing Form filed by One Repc Form filed by More than Person	orting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned						

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr.		Transaction Code (Instr.		Transaction Disposed Of (D) (Instr. 3, 4 and 5 Code (Instr.			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(11501-4)		

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security 8. Price of Derivative Security 3. Transaction 3A. Deemed 5. Number of 6. Date Exercisable and 7. Title and Amount 9. Number of 10. 11. Nature 2 Ownership Form: Execution Date, if any Transaction Code (Instr. 8) Conversion Expiration Date (Month/Day/Year) of Securities Underlying Date Derivative derivative of Indirect (Month/Day/Year) Beneficial or Exercise Securities Securities Price of Derivative Acquired (A) or Disposed Derivative Sec (Instr. 3 and 4) Beneficially Owned Direct (D) or Indirect Ownership (Instr. 4) (Instr. 3) (Month/Day/Year) Security (Instr. 5) Security of (D) (Instr. 3, 4 and 5) Following (I) (Instr. 4) Reported Transaction(s) Amount (Instr. 4) or Number Expiration Date Code v (A) (D) Exercisable Date Title of Shares

(1)

Explanation of Responses:

\$16.11

1. 25% of this option shall vest and become exercisable on January 1, 2020, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.

127,512

А

Remarks:

Stock Option

Buy)

(Right to

## /s/ Margaret Siegel as Attorney-04/12/2019

\$<mark>0</mark>

127,512

\*\* Signature of Reporting Person

<u>in-Fact</u>

Commor

Stock

04/10/2029

Date

127,512

D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

04/11/2019

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.